|
| Press Releases |
|
 |
|
| Monday, October 18, 2021 |
|
|
Eisai and Merck & Co., Inc. (Kenilworth, N.J.) Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer |
| Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted positive opinions recommending approval of the combination of LENVIMA (marketed as Kisplyx in the European Union [EU]. more info >> |
|
| Tuesday, September 28, 2021 |
|
|
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway |
| Eisai Co., Ltd. and Biogen Inc. today announced that Eisai has initiated a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company's investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early Alzheimer's disease (early AD). more info >> |
|
| Monday, September 27, 2021 |
|
|
Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval |
| AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA. more info >> |
|
| Tuesday, September 14, 2021 |
|
|
Eisai to Join The Global Environmental Initiative "RE100" |
| Eisai Co., Ltd. announced today that it has joined "RE100", the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable electricity. more info >> |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021 |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its oncology products and pipeline will be given at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, from September 16 to 21, 2021, including its in-house discovered lenvatinib mesylate and eribulin mesylate. more info >> |
|
| Monday, September 13, 2021 |
|
|
AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients" |
| AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd. announced today that, on September 13, 2021, the companies launched "Humira Support Tool Ordering Service for Patients" an initiative intended to improve patients' adherence to Humira therapy. more info >> |
|
| Tuesday, August 31, 2021 |
|
|
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries |
| Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in five ASEAN (Association of Southeast Asian Nations) member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand. more info >> |
|
| Monday, August 16, 2021 |
|
|
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has launched the anticancer agent EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide), in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). more info >> |
|
| Thursday, August 12, 2021 |
|
|
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC) |
| Eisai and Merck & Co., Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
| Thursday, August 5, 2021 |
|
|
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards |
| Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs, an affiliate of the Japanese Business Federation (Tokyo). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
GMG's THERMAL-XR(R) Awarded Product of the Year at the AIRAH 2024 Awards
Nov 27, 2024 21:59 HKT/SGT
|
|
|
EdgePoint Infrastructure Inks Strategic Partnership with CelcomDigi to expand connectivity in Malaysia at TowerXchange Meet Up Asia 2024 
Nov 27, 2024 21:30 HKT/SGT
|
|
|
Step Into the World of Jean-Michel Basquiat
Nov 27, 2024 20:00 HKT/SGT
|
|
|
Expert Systems Announces FY25 Interim Results
Nov 27, 2024 19:50 HKT/SGT
|
|
|
Kingworld-Longde Life and Health Industrial Park Grand Opening
Nov 27, 2024 19:40 HKT/SGT
|
|
|
Swire Coca-Cola Hong Kong Leverages SAP S/4HANA and SAP Services to Drive Digital Transformation
Nov 27, 2024 19:30 HKT/SGT
|
|
|
Cropmate Berhad IPO Oversubscribed by 84.88 Times
Nov 27, 2024 18:00 HKT/SGT
|
|
|
Quranium Launches QSafe Wallet with Core Layer (L1) Testnet: The Uncrackable Solution for Blockchain Security
Nov 27, 2024 17:20 HKT/SGT
|
|
|
Survey: New Opportunities in Cross-border E-commerce
Nov 27, 2024 17:11 HKT/SGT
|
|
|
Quranium Node Pre-sale Unveiled: Be Part of the Quantum-Uncrackable Revolution
Nov 27, 2024 17:00 HKT/SGT
|
|
|
Q2 Metals Significantly Expands the Cisco Lithium Property in James Bay, Quebec, Canada
Nov 27, 2024 16:30 HKT/SGT
|
|
|
SF Holding successfully listed in Hong Kong
Nov 27, 2024 16:19 HKT/SGT
|
|
|
Ching Lee Holdings (3728.HK) Reports Significant Growth in Interim Results for 2024
Nov 27, 2024 10:32 HKT/SGT
|
|
|
Genetec maintains stable and profitable performance on a lower Q1FY2025 revenue
Nov 27, 2024 10:00 HKT/SGT
|
|
|
RichTech Digital Berhad Signs Underwriting Agreement with KAF Investment Bank Berhad
Nov 27, 2024 10:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
